4D Molecular Therapeutics, Inc. has reported its financial results for the third quarter of 2026, showcasing its continued growth and strategic collaborations in the biological products sector. The company’s performance is significant as it navigates a competitive landscape, particularly in its partnerships with notable firms like Otsuka Pharmaceutical Company Ltd.
Founded in Emeryville, California, 4D Molecular Therapeutics operates under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is listed on the Nasdaq under the ticker FDMT and is classified as a non-accelerated filer and a smaller reporting company.
The latest filing, dated November 12, 2026, provides insights into the company's financial health as of September 30, 2026. Key highlights from the filing include ongoing revenue from collaborations, particularly with the Cystic Fibrosis Foundation and Otsuka Pharmaceutical Company. The company is focused on advancing its product pipeline and enhancing its market position.
“The filing indicates a strong commitment to innovation and collaboration, which are crucial for growth in the biological products industry,” the report notes.
This update may impact various stakeholders, including investors, partners, and competitors in the biological products sector. The emphasis on collaboration with major players like Otsuka Pharmaceutical suggests a strategic approach to expanding market reach and enhancing product offerings.
Looking ahead, further details on future collaborations or product launches may be disclosed in upcoming filings. The filing does not specify what happens next, but the market will be keenly watching 4D Molecular Therapeutics as it continues to build on its recent successes.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










